Ritanserin, a potent serotonin 2A receptor antagonist, represses MEK/ERK signalling pathway to restore PAX6 production and function in aniridia-like cellular model.

MLA

Oved, Keren, et al. “Ritanserin, a Potent Serotonin 2A Receptor Antagonist, Represses MEK/ERK Signalling Pathway to Restore PAX6 Production and Function in Aniridia-like Cellular Model.” Biochemical and Biophysical Research Communications, vol. 582, Dec. 2021, pp. 100–04. EBSCOhost, https://doi.org/10.1016/j.bbrc.2021.10.036.

APA

Oved, K., Zennaro, L., Dorot, O., Zerbib, J., Frank, E., Roux, L. N., Bremond-Gignac, D., Pichinuk, E., & Aberdam, D. (2021). Ritanserin, a potent serotonin 2A receptor antagonist, represses MEK/ERK signalling pathway to restore PAX6 production and function in aniridia-like cellular model. Biochemical and Biophysical Research Communications, 582, 100–104. https://doi.org/10.1016/j.bbrc.2021.10.036

Chicago

Oved, Keren, Léa Zennaro, Orly Dorot, Johanna Zerbib, Elie Frank, Lauriane N Roux, Dominique Bremond-Gignac, Edward Pichinuk, and Daniel Aberdam. 2021. “Ritanserin, a Potent Serotonin 2A Receptor Antagonist, Represses MEK/ERK Signalling Pathway to Restore PAX6 Production and Function in Aniridia-like Cellular Model.” Biochemical and Biophysical Research Communications 582 (December): 100–104. doi:10.1016/j.bbrc.2021.10.036.